Biogen

Biogen Inc. is a leading global biotechnology company specializing in the discovery, development, and commercialization of innovative therapies for neurological, neurodegenerative, immunological, and rare diseases. Founded in 1978 by a group of distinguished scientists, including Nobel Prize laureates, the company has become one of the world’s foremost biotechnology innovators. Headquartered in Cambridge, Massachusetts, USA, Biogen focuses on advancing science to address complex diseases that significantly impact patients’ quality of life.

The company’s research portfolio includes treatments for multiple sclerosis, spinal muscular atrophy (SMA), Alzheimer’s disease, depression, lupus, and other neurological disorders. Biogen invests heavily in cutting-edge technologies such as gene therapy, precision medicine, biomarkers, artificial intelligence, and advanced neuroscience research to accelerate the development of next-generation therapies.

Biogen operates research, manufacturing, and commercial facilities across North America, Europe, and Asia while collaborating with academic institutions, healthcare organizations, and biotechnology partners worldwide. The company maintains rigorous quality standards throughout its manufacturing operations and emphasizes sustainability, ethical business practices, and patient-centered innovation. Through continuous investment in research and strategic collaborations, Biogen remains committed to transforming scientific discoveries into therapies that improve the lives of millions of patients globally.